Zobrazeno 1 - 10
of 56
pro vyhledávání: '"M. Ferrit"'
Publikováno v:
Reumatismo, Vol 76, Iss 3 (2024)
Objective. This paper aims to provide an overview of the use of treatments available for axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) during pregnancy and breastfeeding, according to current national recommendations and international
Externí odkaz:
https://doaj.org/article/c1081ea75d4b49a09233f218ac5bb08c
Publikováno v:
El Farmacéutico Hospitales; mar2022, Issue 223, p13-22, 10p
Publikováno v:
Clinical pharmacy.
Publikováno v:
Colloids and Surfaces A: Physicochemical and Engineering Aspects. 345:26-30
A spectrophotometric study of the reaction of the alkaline hydrolysis of triflusal (TFL) and acetylsalicylic acid (ASA) in the presence of zwitterionic micelles was carried out, with the objective of determining the effects of the hydrophobic and ele
Publikováno v:
Journal of Molecular Liquids. 142:64-71
A spectrophotometric study of the alkaline hydrolysis of two salicylic acid (SA) derived drugs, performed on acetylsalicylic acid (ASA) and triflusal, both in the absence and presence of cationic micelles. In the absence of micelles, a catalytic effe
Publikováno v:
Reumatismo, Vol 75, Iss 2 (2023)
The objective of this study was to evaluate biological disease-modifying anti-rheumatic drugs (bDMARDs) survival in several therapy courses of patients affected by psoriatic arthritis (PsA) and to compare tumor necrosis factor inhibitors (TNFi) and n
Externí odkaz:
https://doaj.org/article/ed7d3057fe9b4d7da9ce54777d6ff41c
Publikováno v:
Journal of Pharmaceutical Sciences. 93:461-469
The new platelet antiaggregant Triflusal or 2-acetoxy-4-trifluoromethylbenzoic acid presents a structural analogy to acetylsalicylic acid (ASA). Alkaline hydrolysis of triflusal was studied in the presence and absence of cationic micelles of N-cetyl-
Autor:
Miguel Ángel Calleja-Hernández, M Carrasco-Gomariz, C Valencia-Soto, F Artime-Rodriguez-Hermida, M Ferrit-Martin, N Martinez-Casanova
Publikováno v:
European Journal of Hospital Pharmacy. 23:A86.1-A86
Background Biological agents are used to treat rheumatic diseases. Patients are initially treated at the recommended dose according to the results of clinical trials but there is no current consensus on what attitude to take following remission. The
Publikováno v:
European Journal of Hospital Pharmacy. 23:A248.3-A249
Background Deviation from the desired beneficial effects of medicines causes drug related problems (DRP). DRP are the cause of morbidity and mortality associated with medicines, and strategies are required to carry out an appropriate approach to this
Autor:
M Rodríguez Goicoechea, MA Calleja Hernández, L Gutiérrez Zúñiga, Caparrós Romero, M Ferrit Martin
Publikováno v:
European Journal of Hospital Pharmacy. 23:A78.3-A79
Background The safety of biologic agents for the treatment of psoriasis has been studied in long term clinical trials with up to 5 years of follow-up. However, observational studies provide the potential to identify safety signals in a real world set